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Abstract
The influence of epigenetics is evident in many fields of medicine today. This is also true in placentology, where
versatile epigenetic mechanisms that regulate expression of genes have shown to have important influence on
trophoblast implantation and placentation. Such gene regulation can be established in different ways and on
different molecular levels, the most common being the DNA methylation. DNA methylation has been shown today
as an important predictive component in assessing clinical prognosis of certain malignant tumors; in addition, it
opens up new possibilities for non-invasive prenatal diagnosis utilizing cell-free fetal DNA methods. By using a well
known demethylating agent 5-azacytidine in pregnant rat model, we have been able to change gene expression
and, consequently, the processes of trophoblast differentiation and placental development. In this review, we
describe how changes in gene methylation effect trophoblast development and placentation and offer our
perspective on use of trophoblast epigenetic research for better understanding of not only placenta development
but cancer cell growth and invasion as well.
1. Introduction
After completing the human genome sequencing in
2000, the world of science thought it overcame the final
barrier to understanding the mystery of life. What it
stumbled upon, however, really has been just another
puzzle and a new riddle to solve. Knowing does not
necessarily imply easy understanding.
Genetics and cell science have revealed in detail what
cells in our body are made of, but have not yet suc-
ceeded in explaining the diversity in morphology and
function that derives from the same genetic material.
Explaining the mechanisms that regulate temporally and
spatially dependent expression of selected genes in guid-
ing cell differentiation and function, for processes as
divergent as embryo development and schizophrenia, is
the ground work of epigenetics [1]. The fact that extrin-
sic environmental stressors can influence chromatin
structure and lead to cell phenotype change, which
could then be passed on to the next generation without
disturbing the DNA sequence, dramatically challenges
the basic Mendelian postulates [2].
Most of the current research in epigenetics focuses on
regulation of gene transcription by changes in chromatin
form and structure, via acquisition of new covalent or
non-covalent bonds, through DNA methylation or his-
tone proteins acetylation, methylation and phosphoryla-
tion [3,4]. Methylation of the DNA CpG base pairs,
located predominantly in the promoter regions of the
genes, disables binding of transcription factors, thus
“silencing” the gene expression, whereas modifications
to histone proteins and nucleosomes influence chroma-
tin form by changing the charge of histone tails and
making the DNA physically either more or less accessi-
ble to transcription factors [5,6].
Though the epigenetic mechanisms are themselves
quite simple, easy to explain and reproduce, the com-
plex network of interactions which they induce in order
to produce a unique pattern of gene expression, is
immensely complex and poses a serious challenge for
current and future research in the field of epigenetics
[7,8]. Despite the complexity, epigenetic research offers
insights that will likely result in better explaining of
diverse entities in human physiology and pathology that
are currently insufficiently understood - entities such as
cell migration and differentiation (e.g. during implanta-
tion, placentation, embryogenesis and organogenesis),
pathology of the placenta (including pre-eclampsia,
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eclampsia, HELLP syndrome and intrauterine growth
restriction syndrome (IUGR)), carcinogenesis, brain
plasticity and effects of environmental factors on
growth, development and health, among many others.
In this regard, certain steps have already been made
toward the practical application of this knowledge in
modern medicine. Thus, methylation status of the
APC1A tumor suppressor gene promoter has been sug-
gested as a novel marker of an unfavourable outcome in
cervical cancer, i.e. prognosis is worse with an increase
in promoter methylation [9]. The relationship between
APC1A methylation and cervical cancer clinical out-
come may be explained by known functions of the
APC1A in cell adhesion and b-catenin inactivation. This
has been confirmed in recent in vitro studies, where
addition of hydralazine to the cervical cancer cell lines
(including HeLa), resulted in demethylation of the APC
promoter and consequent cell growth inhibition and dis-
ruption of the b-catenin expression [10].
Gene inactivation by promoter hypermethylation has
been also discovered within the large group of Ras effec-
tors with tumor suppressor activity (although Ras family
of small GTP-linked proteins may act to promote
tumorigenesis as well, depending on the downstream
activated molecules). For example, NORE1A (RASSF5)
protein is a family member with the typical Ras charac-
teristic domain. Its role as a tumor suppressor is accom-
plished through induction of apoptosis and delay in cell
cycle progression in various cancer cell lines. Thus, it is
frequently silenced in human tumors, most commonly
due to methylation of its promoter [11]. Related protein,
RASSF1A (Ras association domain-containing protein
1), can be inactivated in a similar fashion. NORE1A and
RASSF1A form heterodimers and activate proapoptotic
signals. RASSF1A gene promoter is one of the most
commonly hypermethylated tumor suppressor genes
found in human tumors, and its methylation is in direct
correlation with its gene expression level [12].
2. Rodent placenta as a model for epigenetics of
human placental development
Since mouse and rat placentas are morphologically and
genetically similar to human placenta, the results gath-
ered in epigenetic research in rodents can be applied to
humans [13]. Most important functional features of
both mouse/rat and human placentas are the invasion of
endometrium by trophoblast cells and the nutrient and
gas exchanges in placental labyrinth layer (in rodents;
analogous to the chorionic villi in humans), which is
covered by syncytiotrophoblast laying in direct contact
with maternal blood [14].
Furthermore, several genes, such as Igf2, H19, Mash2,
Hand1, Gcm1 and Met, are found to be important dur-
ing both rodent and human placental development,
indicating common molecular mechanisms [15]. How-
ever, their distinct functions in humans is yet to be
investigated further [14].
Numerous human analogues of the mouse genes have
been identified, such as an analogue of the mouse
Mash2 gene, which is important for the spongiotropho-
blast development. Expression of Mash2 is regulated by
genomic imprinting, since the identical phenotype is
seen in mice with mutations in both alleles (homozy-
gous mice) as well as in those heterozygous mice with
maternally inherited mutant allele, whereas heterozygous
mice with paternally inherited mutant allele remain
unaffected. Mash2 human analogue, HASH2 (Human
Achaete-Scute Homologue 2), is expressed in extravil-
lous trophoblast; since its presence is lacking in andro-
genic hydatidiform moles, its expression is thought to
be imprinted as well [16,17]. Another murine gene,
Gcm-1 (glial cells missing homologue 1), blocks mitosis
and is essential for labyrinth development and syncytio-
trophoblast differentiation; its human analogue, GCM1,
displays similar expression pattern. Inhibition of the
GCM1 in human placental cell lines prevents exravillous
trophoblast differentiation, whereas addition of forsko-
line, an inducer of GCM1 expression, leads to an
increased syncytialization and decreased trophoblast
proliferation. Taken together, alterations in GCM1 gene
expression may explain certain aspects of pre-eclampsia
and IUGR-associated clinical pictures [18].
Since cells making up placenta display unique methy-
lation patterns compared to somatic cells, the placental
development has been recognized as one of the best
model for studying epigenetic mechanisms [19,20]. Dur-
ing the complex processes of implantation and placenta-
tion, coordinated epigenetic regulation ensures that the
sequence of gene expression in cells is accurate and
timely. DNA methylation is thought to be the main epi-
genetic mechanism operating during placental develop-
ment; any disruption in placental methylation pattern
leads to aberrant function of the placenta [21]. The tro-
phoblast cells of the placenta have the lowest 5-methyl-
cytosine content of all human cells (except germ cells),
comparable to hypomethylated levels in cancer cells and
have a unique set of imprinted genes, making them a
rich source for research on the impact of DNA methyla-
tion on physiological and pathological tissue develop-
ment [22-28].
Although rodent placenta represents a suitable model
for epigenetic studies, and as such, a model for placenta-
tion in humans, there are however, certain differences in
epigenetics between rodent and human placentation
that should be kept in mind. In mice, imprinted genes,
of which there are many in the placenta, are largely
maternally expressed and paternally repressed [29]. In
humans, however, gene imprinting mechanism may
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differ, as some imprinted genes are maternally (e.g.
APC, WIF1) and others paternally (SFRP2, RASSF1A)
expressed [30]. Further, the imprinting of the ESX1L
gene is indispensable for placental development in mice,
whereas that same homeobox gene is found not to be
imprinted in humans, during the last trimester of preg-
nancy [31]. Its expression is significantly lower in preg-
nancies associated with IUGR, suggesting that some
idiopathic fetal growth restrictions are associated with
placental dysfunction [32]. Also, expression of RASSF1A
in human placenta is highest in stroma and lowest in
cytotrophoblast, where it is extensively methylated.
Hypermenthylated Rassf1 is found in the placentas of
Rhesus monkeys as well. In the mouse placenta, how-
ever, that same gene is not methylated; additionally,
mice with knocked out Rassf1 are fertile and display no
reproductive disturbances, which shows that this
imprinted gene has not been evolutionary conserved
[33].
The use of experimental animal models inevitably
raises questions about their value for understanding
human physiology and disease. However, animal models
are unavoidable, and as long as one is careful in inter-
preting the results obtained on them, and until those
results are confirmed on human tissues, they are of
great scientific value. The benefit to the use of experi-
mental animals is also the ability to construct null-
mutants for the particular gene of interest, with the aim
of discovering its function in the placenta.
In addition to rodent vs. human, anatomical and phy-
siological differences between mice and rats have to be
appreciated as well. For example, trophoblast invasion
into uterine epithelium is shallow in mice whereas it is
deeper in rats (mesometral triangle) and as such more
similar to humans [34].
The discovery of the cell-free fetal DNA (cffDNA),
which amounts to about 5% in the mother’s circulating
blood, and is being used for fetal RhD status and sex
determination, opens up new possibilities for non-inva-
sive diagnostics [35]. In a light of recent findings, the
above mentioned RASSF1A is being considered as the
potential universal marker to aid detection of fetal
DNA. Namely, since cffDNA is found in anembryonal
pregnancies as well, it is thought that its source is syn-
cytiotrophoblast [36]. The RASSF1A promoter is hyper-
methylated in the placenta and hypomethylated in the
mother’s blood - this pattern of methylation makes it
possible to discriminate between the placental and
mother’s RASSF1A [37]. In addition, RASSF1A methyla-
tion level can discriminate between normal pregnancy
and pre-eclampsia: whereas there are no differences in
methylation between placentas, plasma RASSF1A is
about four times more methylated in the pre-eclampsia
patients than in women with normal pregnancies. Y-
chromosome detection has been used as a marker of
elevation of fetal DNA before the onset of pre-eclamp-
sia, but methods based on RASSF1A methylation level
now make non-invasive diagnosis of pre-eclampsia pos-
sible as well [38].
Finally, in addition to mere presence or absence of
some tissue-specific factors, recent findings suggest that
for certain genes, such as Cdx2 and Oct4, their amount
relative to other factors is important as well. Such ratio
of factors leads to establishment of a specific cell types,
in this case trophoblast and embryoblasts cells inside
the blastocyst [39].
We cannot close this chapter without addressing tro-
phoblast stem cells, which so far have been successfully
isolated from the mouse. As for the rat, a recently pub-
lished report describes for the first time isolation and
culture of cells that express markers specific for rat tro-
phoblast stem cells (in the presence of FGF4) and their
ability to differentiate into trophoblast giant cells (when
FGF4 is removed from the medium) [40]. In human
cells, overexpression of a single transcription factor,
Oct4, in trophoblast cells is sufficient for their repro-
gramming into pluripotent cells (OiPS, Oct4-induced
pluripotent cells). OiPS bear the epigenetic characteris-
tics of embryonal stem cells (including reactivation of
the inactivated X-chromosome, Oct4 and Nanog gene
promoters hypomethylation and Elf5 gene promoter
methylation) and are capable of differentiation into cells
of all three embryonal layers [41].
3. Our epigenetic point of view on trophoblast
diferentiation and development of placenta
The DNA methylation can be changed by exposure of
cells to a well known demethylating agent 5-azacytidine
(5azaC), which incorporates into both DNA and RNA
molecules [42]. In DNA, it inhibits methylation by trap-
ping DNA methyltransferase (Dnmt), resulting in its
deactivation [43]. The 5azaC is a well known antineo-
plastic citidine analogue that, due to its inhibition of
Dnmt and consequent promoter hypomethylation of
transcriptionally silenced genes and cytotoxicity, is being
used in therapies of myelogenous leukaemia and myelo-
dysplastic syndrome [44]. For example, it has been
shown that in the presence of 5azaC, the inhibitory
effect of glucose on the expression of hGH-V (human
placental growth hormone) is reduced, as 5azaC hypo-
methylates hGH-V (normally, high glucose levels lower
the endogenous hGH-V mRNA) [45]. The potential use
of 5azaC in therapy of solid tumors is currently being
tested in clinical trials.
DNA methylation is considered as a barrier mechan-
ism, one that in, e.g., globin genes ensures the balance
between genes being accessible or not to the transcrip-
tion machinery. Namely, in the absence of methylation,
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other accessory mechanisms of repression are not suffi-
cient for histone deacetylation and consequent gene
inactivation characteristic for non-erythroid cells. Thus,
in these cells, all globin genes are in the form of hetero-
chromatine, packed in the conformation that is insensi-
tive to DNAse I and replicates late. However,
simultaneous exposure to 5azaC and biturates is capable
of stimulating the gamma-globin expression in patients
with beta-hemoglobinopathies [46]. Over 30 genes with
hypermethylated promoters in human lung cancers have
been described in the last two decades. Cigarette smoke
condensate hypermethylates promoters of the genes
involved in epithelial-mesenchymal transition; thus,
when human bronchial epithelial cell lines, exposed to
cigarette smoke concentrate, are treated with 5azaC and
trichostatin A (histone deacetylase inhibitor), a third of
the silenced genes become reactivated [47].
The assumption that the effects of 5azaC are mediated
solely through changes in DNA methylation, however, is
not correct. Numerous studies have emerged in recent
years demonstrating that the effects of 5azaC are cell
and gene specific. For example Komashko and Farnham
showed that (1) 5-azacytidine treatment results in large
changes in gene regulation with distinct functional cate-
gories of genes showing increased and decreased levels;
(2) most genes that show altered expression are not
regulated by promoters that display DNA methylation
prior to the treatment; (3) certain gene classes switch
their repression mark upon treatment with 5-azacyti-
dine; and (4) most changes in gene expression are not
due to relief of repression mediated by DNA or histone
methylation [48].
The prevalent outcome of DNA demethylation is
expression of previously silenced genes, made possible
by enabling attachment of transcription factors to the
genes, with consequent gene transcription and protein
synthesis up-regulation [49]. In our laboratory, after
administering 5azaC to pregnant rats on different gesta-
tion days, we concluded that expression of certain genes
is enhanced or even activated, in agreement with other
investigators. Specifically, when looking at the distribu-
tion of placental glycoproteins, we detected some in the
experimental group (with 5azaC) that were not present
in the control (without 5azaC) rats [50].
On the other hand, expression of some genes is sup-
pressed, rather than activated, upon demethylation. The
well known example is the regulation of expression of
closely linked and imprinted genes H19 (transcribed
from maternally inherited allele) and Igf2 (transcribed
from paternally inherited allele) [51]. The Igf2 was the
first discovered imprinted gene - its targeted mutation
leads to dwarfism in heterozygous individuals, but only
when paternal (and not maternal) gene is affected.
Growth reduction in newborns is identical in
heterozygous individuals with mutated paternal gene
and in recessive homozygous individuals, suggesting that
the activity of the Igf2 gene is influenced only by the
father [52]. Imprinted genes tend to cluster, which
makes it easier to control their expression. This control
is the responsibility of the cis-regulatory sites, such as
the “imprinting control regions” (ICR) or “differentially
methylated domains” (DMD), their characteristic being
that they are always methylated on one of the two par-
ental alleles [53,54]. If deletions in these sites occur,
imprinting is lost and both alleles become expressed
[55]. One of the best studied ICRs is the one situated
within the H19/Igf2 imprinted gene complex, where
activity of these two genes is dependent on the methyla-
tion status of the control region situated between them
[56,51]. Specifically, on paternal chromosome, ICR is
methylated, which makes H19 gene inactive and allows
expression of Igf2 [57]. On maternal chromosome, ICR
is not methylated and behaves as an “isolator”, i.e. regu-
latory element that influences gene expression, onto
which CTCF transcriptional regulatory protein can bind
(it recognizes CCCTC sequence, CCCTC-binding factor
(zinc finger protein)). As a result of CTCF binding, Igf2
promoter enhancer activity is inhibited and, conse-
quently, Igf2 becomes inactive, whereas H19 gene is
now active [58]. Thus, methylation can activate gene
activity in an indirect manner, via blockage of an isola-
tor [59]. The regulation of H19 gene expression is
direct, since its methylation introduces inactive, i.e.
imprinted site, and thus methylation directly influences
its promoter activity [60].
Furthermore, in our research of epigenetic control of
rat placentation, we obtained other interesting results
concerning the proliferating capacity of trophoblast. We
observed that 5azaC (i.e. hypomethylation) increases the
expression of PCNA (proliferating cell nuclear antigen, a
marker of cell proliferation) in trophoblast cells of rat
placenta, with peak proliferation present when 5azaC is
administered during the periimplantation period, from
4th to 6th day of gestation [50].
Recently, epigenetic research has gone even further by
showing that methylation of the CRE (cAMP response
element) sequence (TGACGTCA) enhances DNA bind-
ing of the C/EBPa transcription factor (CCAAT/enhan-
cer-binding protein alpha), a protein critical for
activation of differentiation of various cell types [61].
Transfection assays show that C/EBPa activates CRE
sequence only when it is methylated, whereas experi-
mental demethylation following 5azaC treatment
diminishes C/EBPa binding and activation of the promo-
ters during differentiation [61]. The lack of some glyco-
proteins in our experimental rat groups after 5azaC
administration could probably be explained in similar
fashion.
Serman and Dodig Clinical Epigenetics 2011, 3:7
http://www.clinicalepigeneticsjournal.com/content/3/1/7
Page 4 of 6
Moreover, research on the gene expression controlling
effects of 5azaC is having a significant contribution for
the understanding of tumor cell biology and mechan-
isms of oncogenesis as well. For example, in our labora-
tory, we have developed a model system for analysis of
behaviour of rat trophoblast cells, which resemble
tumor cells in many of their functional characteristics.
In this system, trophoblast cells are transplanted under
the rat kidney capsule and, mimicking cancer cell lines,
allowed to grow and expand [62]. Then, post-implanta-
tion, cells are exposed to demethylating activity of
5azaC for various lengths of time and their growth and
differentiation in vivo, as well as expression of a range
of differentiation and cancer-associated genes in cells ex
vivo, are being determined.
4. Conclusion
The DNA methylation, as one of the most important
epigenetic mechanisms of gene expression control, offers
a more complete insight into how this control is
achieved in cells. It enables us to understand how a cer-
tain pattern of gene expression is accomplished in
healthy tissues and in diseased cells of various patholo-
gies. Trophoblast cells are the principal cells of normal
embryonal implantation and placentation, as well as
many pathologic conditions of pregnancy, such as
eclampsia (where invasion of trophoblast cells is thought
to be too shallow) or placenta accreta or preccreta
(where invasion of cells is too deep). Epigenetic mechan-
isms can help explain the function of trophoblast cells
in these conditions. By exposing these cells to the DNA
demethylating agent 5azaC, we have been able to artifi-
cially demethylate or hypomethylate their DNA and,
thus, interfere with expression of the genes crucial for
the functioning of the trophoblast cells during embryo-
genesis. Such manipulated trophoblast cells have been
employed in our unique rat animal model, a combina-
tion of in vitro, in vivo and ex vivo cell growth. We have
used this model to investigate not only placental devel-
opment, but mechanisms of tumor cell growth as well,
as trophoblast and malignant cells share many of their
functional characteristics, the most important being tis-
sue invasion. Thus, determination of the sequence of
molecular events that lead to timely and tightly con-
trolled blockage of invasion of trophoblast cells during
implantation could be directly translated into explaining
why such mechanisms have been lost in cancer cells
during metastasis.
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